Biogen Idec: Q3 Clues To Value Seeking Alpha In addition Daclizumab HYP showed good Phase 2b trial results. Dexpramipexole for Lou Gehrig's (ALS) disease Phase III trial became fully enrolled recently. Third quarter (Q3) results released on October 28, along with the analyst conference call, ... |
